Company Announcement no. 14/2011

To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, November 30, 2011


Articles of Association


Hørsholm, 30. November 2011 – Veloxis Pharmaceuticals A/S (OMX: VELO), have
today registered new articles of association with the company register.

The new articles of association is attached.

For more information

John D. Weinberg Johnny Stilou
SVP, Commercial Operations and Investor Relations CFO
Mobil: +1 908 304 3389 Mobil: +45 2055 3852
Email: [email protected] Email: [email protected]

About Veloxis Pharmaceuticals

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis
Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company.
Clinical development is the core of Veloxis’ efforts to develop a product
portfolio which includes the Company’s lead product candidate, LCP‐Tacro™, for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. Veloxis adapts new technologies on a fast
commercial timetable. Veloxis’ unique, patented delivery technology, MeltDose®,
can improve absorption and bioavailability ‐ at low‐scale up costs ‐ not only
for a broad spectrum of drugs already on the market but also for new chemical
entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the
U.S. market and a diversified near and medium term pipeline with three clinical
stage product candidates and a number of projects in preclinical development.
Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX:
VELO.

For further information, please visit www.veloxis.com.